<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147676</url>
  </required_header>
  <id_info>
    <org_study_id>7213-2/1</org_study_id>
    <nct_id>NCT04147676</nct_id>
  </id_info>
  <brief_title>Evaluation of Centralised TB Assay Solutions</brief_title>
  <official_title>Multicentre Trial to Assess the Performance of Centralized Assay Solutions for Detection of MTB and Resistance to Rifampin and Isoniazid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tuberculosis (TB) remains a life-threatening disease partly due to increasing incidence of
      multidrug and extensively drug-resistant TB. Diagnostic based on culture and conventional
      drug susceptibility testing using media take several weeks leading to prolonged periods of
      ineffective therapy and ongoing transmission. Development of rapid molecular diagnostic tests
      for the identification of Mycobacterium tuberculosis (MTB) and drug resistance has become a
      high priority.

      The Xpert® MTB/RIF Assay does not provide information on INH-resistance and the LPA is only
      recommended for use in smear-positive samples, complex to perform and requires manual
      interpretation. Several novel assays have been recently developed/CE-marked offering high
      sample throughput and higher sensitivity for detection of MTB, RIF- and INH-resistance in
      centralized laboratories. However, published data on their performance and operational
      characteristics is extremely limited.

      This is a prospective, multicentre, diagnostic accuracy trial in which the performance of
      centralised TB assay solutions will be assessed at the intended setting of use with culture,
      phenotypic DST and sequencing as reference standard.

      Potential trial participants will be identified at participating TB clinics or hospitals
      (enrolment sites). Sputum samples will be collected and transported to the associated TB
      reference laboratories (testing sites).

      In order for the results of this trial to be generalizable, adults with symptoms compatible
      with pulmonary TB undergoing evaluation will be screened for inclusion at geographically
      diverse participating centres in high burden TB countries. Additionally, to supplement the
      drug-resistant cases to timely achieve accurate performance estimates, well-characterized
      frozen sputum samples from the FIND specimen bank will be used.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy for MTB detection</measure>
    <time_frame>four to six months</time_frame>
    <description>clinical sensitivity and specificity by smear-status measured against mycobacterial culture as the reference standard.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for RIF/INH detection</measure>
    <time_frame>four to six months</time_frame>
    <description>clinical point estimates of sensitivity and specificity measured against a composite reference standard of phenotypic DST and targeted sequencing.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operational characteristics:</measure>
    <time_frame>four to six months</time_frame>
    <description>description of operator experience with the assays through daily observed usage and user appraisal questionnaires.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1700</enrollment>
  <condition>Tuberculosis</condition>
  <condition>Drug-resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>TB suspects</arm_group_label>
    <description>Sputum specimens will be collected from TB suspects enrolled in the study.
The specimens will be tested with
Roche cobas MTB - for the detection of Mycobacterium tuberculosis complex
Roche cobas MTB-RIF/INH - all specimens that are Mycobacterium tuberculosis complex positive will be reflexed to the Roche cobas MTB-RIF/INH test for the detection of resistance to rifampicin and isoniazid
Hain FluoroType MTBDR - for the detection of Mycobacterium tuberculosis complex and the detection of resistance to rifampicin and isoniazid</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Sputum specimens M. tuberculosis cultures isolates from patient specimens
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients in whom pulmonary TB is suspected. Additionally, well-characterized RIF-resistant
        and INH-resistant samples will be used to supplement drug-resistant cases.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients are eligible to be included as trial participants only if all of the following
        inclusion criteria apply:

          -  Aged ≥18 years

          -  Clinical suspicion of pulmonary TB including cough ≥2 weeks (or any duration if HIV
             positive ) and ≥1 other symptom typical of pulmonary TB listed below:

               -  Fever

               -  Malaise

               -  Recent weight loss

               -  Night sweats

               -  Contact with active case

               -  Haemoptysis

               -  Chest pain

               -  Loss of appetite

        Exclusion Criteria:

        Participants are excluded from the trial if any of the following exclusion criteria apply:

          -  Unwilling or unable to provide informed consent

          -  Unwilling to provide four sputum specimens at enrolment i.e. 2x sputa on day 1 and 2x
             sputa on day 2 (up to 1 week from enrolment)

          -  Patients with only extra-pulmonary TB signs &amp; symptoms

          -  Receipt of any dose of TB treatment within 6 months prior to enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Margaretha de Vos, PhD</last_name>
    <phone>+41 (0) 22 749 29 31</phone>
    <email>margaretha.devos@finddx.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pamela Nabeta, MD</last_name>
    <phone>+41 (0) 22 710 27 87</phone>
    <email>pamela.nabeta@finddx.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Center for Tuberculosis and Lung Diseases</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaza Avaliani, MD</last_name>
      <phone>(+995)32910251</phone>
    </contact>
    <contact_backup>
      <last_name>Nestani Tukvadze, PhD</last_name>
      <phone>(+995)32910769</phone>
      <email>marikushane@yahoo.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Forschungszentrum Borstel. Leibniz Lungenzentrum (Borstel)</name>
      <address>
        <city>Borstel</city>
        <zip>23845</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Maurer, MD</last_name>
      <phone>+49 4537 188 (2110)</phone>
      <email>fmaurer@fz-borstel.de</email>
    </contact>
    <contact_backup>
      <last_name>Anne-Katrin Witt, PhD</last_name>
      <phone>+49 4537 188 (2050)</phone>
      <email>awitt@fz-borstel.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Indian Council of Medical Research (ICMR) Regional Medical Research Centre</name>
      <address>
        <city>Bhubaneswar</city>
        <zip>751023</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sanghamitra Pati, MD</last_name>
      <phone>+91 674 230 1332</phone>
      <email>drsanghamitra12@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Dasarathi Das, MD</last_name>
      <phone>+91 943 79 20085</phone>
      <email>drdas60@rediffmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>National Institute for Research in Tuberculosis</name>
      <address>
        <city>Chennai</city>
        <zip>600031</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Priya Rajendran, MD</last_name>
      <phone>044 -28369660</phone>
      <email>priya.r@nirt.res.in</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Phthisiopneumology &quot;Ch. Draganiuc&quot; (PPI NRL), Moldova</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valeriu Crudu, MD</last_name>
      <phone>+373 22 572245</phone>
      <email>valeriu.crudu@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ecaterina Noroc, PhD</last_name>
      <phone>+373 22 794570</phone>
      <email>ecaterina.noroc@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Division of Wits Health Consortium (DMMH)</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Scott, PhD</last_name>
      <phone>+27 11 489 8567</phone>
      <email>lesley.scott@wits.ac.za</email>
    </contact>
    <contact_backup>
      <last_name>Anura David, MSc</last_name>
      <phone>+27 11 489 8573</phone>
      <email>anura.david@nhls.ac.za</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Georgia</country>
    <country>Germany</country>
    <country>India</country>
    <country>Moldova, Republic of</country>
    <country>South Africa</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 30, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

